David E. Nix

7.4k total citations · 2 hit papers
140 papers, 5.8k citations indexed

About

David E. Nix is a scholar working on Pharmacology, Epidemiology and Infectious Diseases. According to data from OpenAlex, David E. Nix has authored 140 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Pharmacology, 50 papers in Epidemiology and 36 papers in Infectious Diseases. Recurrent topics in David E. Nix's work include Antibiotics Pharmacokinetics and Efficacy (66 papers), Antibiotic Resistance in Bacteria (29 papers) and Pneumonia and Respiratory Infections (18 papers). David E. Nix is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (66 papers), Antibiotic Resistance in Bacteria (29 papers) and Pneumonia and Respiratory Infections (18 papers). David E. Nix collaborates with scholars based in United States, Saudi Arabia and Australia. David E. Nix's co-authors include Jerome J. Schentag, Alan Forrest, Mary C. Birmingham, Charles H. Ballow, Charles A. Peloquin, Thomas F. Goss, Claude Bohuon, Michael F. Wilson, M. Assicot and Paresh Dandona and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Clinical Endocrinology & Metabolism and Clinical Microbiology Reviews.

In The Last Decade

David E. Nix

135 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

1993 906 citations Alan Forrest, David E. Nix et al. Antimicrobial Agents and Chemotherapy profile →
Procalcitonin increase after endotoxin injection in normal subjects.

1994 753 citations David E. Nix et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David E. Nix United States	39	2.7k	2.7k	1.4k	1.4k	564	140	5.8k
H. Lode Germany	48	4.1k 1.5×	2.5k 0.9×	1.2k 0.8×	2.3k 1.7×	309 0.5×	277	8.3k
Richard Quintiliani United States	42	2.6k 0.9×	3.4k 1.3×	1.9k 1.3×	1.9k 1.4×	1.0k 1.8×	260	6.9k
Charles H. Nightingale United States	38	2.0k 0.7×	3.1k 1.1×	1.9k 1.3×	950 0.7×	525 0.9×	209	5.1k
Konstantinos Z. Vardakas Greece	46	2.6k 1.0×	1.8k 0.7×	2.4k 1.7×	1.7k 1.3×	843 1.5×	96	6.2k
Petros I. Rafailidis Greece	47	3.3k 1.2×	1.8k 0.7×	3.1k 2.2×	1.9k 1.4×	549 1.0×	116	7.7k
Ethan Rubinstein Canada	45	2.4k 0.9×	1.8k 0.7×	1.8k 1.2×	2.4k 1.7×	877 1.6×	140	6.8k
Larry H. Danziger United States	41	1.9k 0.7×	1.5k 0.5×	1.4k 1.0×	1.2k 0.9×	349 0.6×	153	5.4k
B. Fantin France	40	1.7k 0.6×	1.4k 0.5×	1.6k 1.1×	1.8k 1.3×	733 1.3×	202	5.2k
Michael Neely United States	38	2.4k 0.9×	3.4k 1.3×	962 0.7×	2.7k 2.0×	936 1.7×	178	6.7k
Francesco Giuseppe De Rosa Italy	36	2.0k 0.7×	1.2k 0.5×	1.6k 1.1×	1.7k 1.2×	608 1.1×	285	5.7k

Countries citing papers authored by David E. Nix

Since Specialization

Citations

This map shows the geographic impact of David E. Nix's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David E. Nix with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David E. Nix more than expected).

Fields of papers citing papers by David E. Nix

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David E. Nix. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David E. Nix. The network helps show where David E. Nix may publish in the future.

Co-authorship network of co-authors of David E. Nix

This figure shows the co-authorship network connecting the top 25 collaborators of David E. Nix. A scholar is included among the top collaborators of David E. Nix based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David E. Nix. David E. Nix is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nix, David E., Fekade B. Sime, & Jason D. Roberts. (2025). Correction of posaconazole concentrations for hypoalbuminemia. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 45(6). 324–331.

Nix, David E., et al.. (2025). Pharmacokinetics of nikkomycin Z following multiple doses in healthy subjects. Antimicrobial Agents and Chemotherapy. 69(7). e0039525–e0039525. 1 indexed citations

Mohajer, Mayar Al, David Slusky, David E. Nix, & Catia Nicodemo. (2025). Investigating socioeconomic deprivation and antibiotic prescribing among older medicare patients using an instrumental variable approach. Antimicrobial Stewardship & Healthcare Epidemiology. 5(1). e110–e110.

Patanwala, Asad E., David E. Nix, Thomas Hills, & Brian L. Erstad. (2024). A National Retrospective Cohort Study Comparing the Effects of Cefepime Versus Piperacillin-Tazobactam on the Development of Severe Acute Kidney Injury in Patients With Septic Shock. Clinical Infectious Diseases. 80(4). 770–776. 2 indexed citations

Mohajer, Mayar Al, David Slusky, David E. Nix, & Catia Nicodemo. (2024). Medical school ranking and provider outpatient Medicare Part D claims for antibiotics among older patients in the USA. JAC-Antimicrobial Resistance. 6(6). dlae191–dlae191. 1 indexed citations

Nix, David E., et al.. (2024). Challenges Facing Antimicrobial Stewardship Programs in the Endemic Region for Coccidioidomycosis. Open Forum Infectious Diseases. 11(6). ofae041–ofae041. 1 indexed citations

Lainhart, William, et al.. (2023). Risk for primary cephalosporin resistance in Gram-negative bacteremia. SHILAP Revista de lepidopterología. 3(1). e121–e121. 2 indexed citations

Al‐Obaidi, Mohanad, Luis Ostrosky‐Zeichner, & David E. Nix. (2023). Trends of Azole Antifungal Prescription in the United States: Medicare Part D Provider Utilization and Payment Data Analysis. Open Forum Infectious Diseases. 10(8). ofad345–ofad345. 3 indexed citations

Erstad, Brian L. & David E. Nix. (2023). Medication dosing in adult patients with reduced lean body mass and kidney injury: A focus on cystatin C. American Journal of Health-System Pharmacy. 80(12). 712–718. 2 indexed citations

10.

Erstad, Brian L. & David E. Nix. (2022). Considerations When Using Body Mass Index as a Size Descriptor. Annals of Pharmacotherapy. 57(1). 107–109. 1 indexed citations

11.

Nix, David E., et al.. (2021). The relationship of vancomycin 24-hour AUC and trough concentration. American Journal of Health-System Pharmacy. 79(7). 534–539. 10 indexed citations

12.

Nix, David E. & Brian L. Erstad. (2021). Creatinine Assessment in Non–Steady-State Conditions: A Critical Review. Annals of Pharmacotherapy. 55(12). 1536–1544.

13.

Nix, David E., et al.. (2020). A Critical Evaluation of Newer β-Lactam Antibiotics for Treatment of Pseudomonas aeruginosa Infections. Annals of Pharmacotherapy. 55(8). 1010–1024. 31 indexed citations

14.

Grizzle, Amy J., Leslie Wilson, David E. Nix, & John N. Galgiani. (2020). Clinical and Economic Burden of Valley Fever in Arizona: An Incidence-Based Cost-of-Illness Analysis. Open Forum Infectious Diseases. 8(2). ofaa623–ofaa623. 21 indexed citations

15.

Barletta, Jeffrey F., et al.. (2000). Population Pharmacokinetics of Aminoglycosides in Critically Ill Trauma Patients on Once-Daily Regimens. PubMed. 49(5). 869–872. 41 indexed citations

16.

Schentag, Jerome J., et al.. (1998). Pharmacodynamic Interactions of Antibiotics Alone and in Combination. Clinical Infectious Diseases. 27(1). 40–46. 43 indexed citations

17.

Nix, David E., et al.. (1996). The Audit Oversight Function in Municipalities of Greater Than 100,000 Population When an Audit Committee Is Not Used. 45(3). 32. 2 indexed citations

18.

Forrest, Alan, et al.. (1994). Pharmacodynamic interactions of ciprofloxacin , piperacillin , and piperacillin/tazobactam in volunteer subjects. 34. 118. 1 indexed citations

19.

O’Connor, G. Richard, et al.. (1993). Focus on itraconazole: A broad-spectrum antifungal agent for treatment of blastomycosis and histoplasmosis. 28(1). 2 indexed citations

20.

Nix, David E., et al.. (1992). Dose-Ranging Pharmacokinetic Study of Ciprofloxacin after 200-, 300-, and 400-mg Intravenous Doses. Annals of Pharmacotherapy. 26(1). 8–10. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact